ALNY News 68.05 08/20/2014 04:30:56 Alnylam Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alnylam Pharmaceuticals (ALNY) 68.05 $ALNY

Alnylam's Q2 Loss Wider-than-Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 11:40AM CDT
Alnylam Pharmaceuticals Inc.'s (ALNY) second quarter 2014 loss of 63 cents per share was wider than the Zacks Consensus Estimate of a loss of 54 cents.

Alnylam Pharmaceuticals Reports Second Quarter 2014 Financial Results and Highlights Recent Period Activities
Business Wire - Thu Aug 07, 3:00PM CDT
--- Reported Initial Positive Top-Line Data from Phase 1 Clinical Trial with ALN-AT3, Demonstrating Statistically Significant Knockdown of Antithrombin (AT) and Increase in Thrombin Generation -

The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast "ALN-PCSsc for the Treatment of Hypercholesterolemia"
Business Wire - Thu Aug 07, 8:43AM CDT
The Medicines Company (NASDAQ:MDCO) today announced that in collaboration with Alnylam Pharmaceuticals (NASDAQ:ALNY) it will be hosting the "ALN-PCSsc for the treatment of Hypercholesterolemia" RNAi Roundtable webcast on August 14, 2014. Event details are below.

Alnylam Receives Orphan Drug Designations in the European Union for ALN-AT3, an RNAi Therapeutic in Development for the Treatment of Hemophilia
Business Wire - Thu Aug 07, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designations for ALN-AT3 as an orphan medicinal product for the treatment of hemophilia A and hemophilia B. Alnylam is developing ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT), for the treatment of hemophilia and other Rare Bleeding Disorders (RBD).

Alnylam Pharmaceuticals Down 13.8% Since SmarTrend Downtrend Call (ALNY)
Comtex SmarTrend(R) - Mon Aug 04, 9:50AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on June 27th, 2014 at $62.37. In approximately 1 month, Alnylam Pharmaceuticals has returned 13.81% as of today's recent price of $53.76.

Sanofi Beats on Q2 Earnings, View Up on Strong Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 8:10AM CDT
Sanofi (SNY) reported second quarter 2014 business earnings of 80 cents per American Depositary Share.

Biotech Stock Mailbag: Arrowhead, Catalyst Pharma
at The Street - Fri Aug 01, 7:06AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.

Alnylam to Webcast Conference Call Discussing Second Quarter 2014 Financial Results
Business Wire - Thu Jul 31, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the second quarter ending June 30, 2014 on Thursday, August 7, 2014, after the U.S. financial markets close.

Alnylam to Host Additional Events in "RNAi Roundtable" Webcast Series
Business Wire - Tue Jul 29, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has added three new events to its series of online "RNAi Roundtables" that it is hosting during July and August. Each event will be webcast live on the Investors section of the company's website, www.alnylam.com. An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.

Downtrend Call Working As Alnylam Pharmaceuticals Stock Falls 13.2% (ALNY)
Comtex SmarTrend(R) - Mon Jul 28, 9:21AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on June 27th, 2014 at $62.37. In approximately 1 month, Alnylam Pharmaceuticals has returned 13.21% as of today's recent price of $54.13.

Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Conjugate-Based Delivery of RNA Therapeutics
Business Wire - Tue Jul 22, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Manoharan et al. patent application 13/693,478. The '478 patent application includes newly allowed claims directed to compositions including those comprising a modified RNA agent linked to a biantennary or triantennary ligand. Specifically, the allowed application includes claims that broadly cover single-stranded or double-stranded, chemically modified RNA therapeutics conjugated with an N-acetylgalactosamine (GalNAc) ligand independent of length, sequence, or disease target. The allowance of this patent application represents a major advance in Alnylam's intellectual property (IP) estate, since GalNAc-siRNA conjugates enable potent and durable silencing of liver-expressed disease genes with subcutaneous dose administration and a wide therapeutic index. Importantly, this delivery approach is a key component of the company's execution on its "Alnylam 5x15" and broader genetic medicine product strategy.

Shares of ALNY Down 14.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Jul 16, 9:14AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on June 27th, 2014 at $62.37. In approximately 3 weeks, Alnylam Pharmaceuticals has returned 14.81% as of today's recent price of $53.13.

What RXi Pharmaceuticals' Move to the Russell Microcap Index Means
ACCESSWIRE - Wed Jul 09, 8:48AM CDT
WHITEFISH, MT / July 9, 2014 / RXi Pharmaceuticals Corp. (NASDAQ: RXII), a biotechnology company focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, recently began trading on the Russell Microcap index on June 27, 2014. Membership on the index remains for one year and is based on market cap and style attributes.

Patient Enrollments, Board Appointments, Acquisitions, and Technical Updates - Analyst Notes on Questcor, Synta, Clovis, Alnylam and Intrexon
PR Newswire - Tue Jul 08, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Clovis Oncology, Inc. (NASDAQ: CLVS), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Intrexon Corporation (NYSE: XON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4522-100free.

Growth and Dividends: Europe's Best Pharma Stock
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jul 07, 4:00PM CDT
This stock is making smart investments in biotech -- and not just through partnerships, but through actual equity investments in biotechs like  Regeneron  and  Alnylam Pharmaceuticals  . It's a smart play for income investors (3.5% dividend yield)...

Alnylam to Host "RNAi Roundtable" Webcast Series
Business Wire - Mon Jul 07, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast a series of online "RNAi Roundtables" during July and August. Alnylam scientists and key clinical collaborators will review recent progress from several of the "Alnylam 5x15" programs and discuss the related disease areas. Each event will be webcast live on the Investors section of the company's website, www.alnylam.com. An audio replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.

Alnylam Elects Amy Schulman to its Board of Directors
Business Wire - Wed Jul 02, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the election of Amy W. Schulman to its Board of Directors. Ms. Schulman is the former Executive Vice President and General Counsel of Pfizer Inc., and served as the Business Unit Lead for Pfizer's Consumer Healthcare business. She currently serves on the faculty of Harvard Business School as a Senior Lecturer.

Alnylam Added to Russell 1000 Index as a Member of the Large-Cap Segment of the U.S. Equity Universe
Business Wire - Mon Jun 30, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has been added to the Russell 1000 Index, effective June 27, 2014. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe. It is a subset of the Russell 3000 Index and includes approximately 1000 of the largest securities based on a combination of their market cap and current index membership.

Senior Notes Offerings, Study Findings, Recognitions, Accreditations, and Collaborations - Analyst Notes on Tenet, Hologic, PAREXEL, Centene and Alnylam
PR Newswire - Mon Jun 30, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Tenet Healthcare Corp (NYSE: THC), Hologic, Inc. (NASDAQ: HOLX), PAREXEL International Corporation (NASDAQ: PRXL), Centene Corp (NYSE: CNC) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4251-100free.

Look for Shares of Alnylam Pharmaceuticals to Potentially Rebound after Yesterday's 3.73% Sell Off
Comtex SmarTrend(R) - Thu Jun 26, 5:38PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $64.08 to a high of $67.49. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $65.08 on volume of 821,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 210

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 49

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 360

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 0

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 349

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 98

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 16

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 138

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 548

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading

Top 5 Most Recently Viewed Articles

TuHURA Biosciences to Showcase Innovations at Major Investment Event

Updated Category News Views 109

TuHURA Biosciences to Present at Investment Conference TuHURA Biosciences, Inc. (NASDAQ: HURA), a pioneering Phase 3 immune-oncology company at the forefront of developing innovative therapeutics, has announced a significant presentation in the investment world. Management is set to showcase their work at the 27th Annual H.C. Wainwright Global Investment Conference, an...

Continue Reading
PennantPark Investment Corporation Enhances CLO Management Strategy

Updated Category News Views 123

PennantPark Investment Corporation Expands CLO Platform MIAMI — PennantPark Investment Corporation (the “Company”) (NYSE: PNNT) has successfully established a strong foothold in the middle market with the recent closing of a $400.5 million debt securitization through its joint venture, PennantPark Senior Loan Fund, LLC ("PSLF"). This significant achievement is part...

Continue Reading
Freeport-McMoRan Exceeds Earnings Expectations Amid Rising Copper Prices

Updated Category News Views 50

Freeport-McMoRan Exceeds Earnings Estimates In a recent financial report, Freeport-McMoRan (NYSE: FCX) showcased its ability to navigate the dynamic mining landscape, particularly benefitting from the surge in copper prices. The company announced a substantial profit that surpassed third-quarter expectations, drawing significant attention from investors and analysts...

Continue Reading
WellsCare and Celltrion Canada Unite for Pain Relief Solutions

Updated Category News Views 126

WellsCare Expands Reach with Celltrion Partnership WellsCare, a pioneering medical technology startup based in South Korea, has forged a promising alliance with Celltrion Canada, a renowned subsidiary of global biopharmaceutical giant Celltrion. This collaboration marks a significant milestone in the development of advanced wearable technology aimed at offering effective...

Continue Reading
Elon Musk Addresses Violence Concerns Amid Political Tensions

Updated Category News Views 524

Elon Musk Issues Stark Warning on Violence at Rally Elon Musk stirred significant debate after his virtual appearance at a far-right rally in the UK, where he alerted attendees to an impending threat of violence. His stark statement, "violence is coming, fight back, or die," has reverberated through political discussions and media outlets alike. Details of the Rally...

Continue Reading